C-Path European Nonprofit Established in Amsterdam
C-Path in Europe works seamlessly with its U.S. counterpart to advance the development of novel regulatory-endorsed methodologies to accelerate medical product developmentContinue reading
Author Archive: Roxan Olivas
C-Path and Tufts Medical Center Collaborate on EHR Data Transfer
The endeavor represents a major milestone for C-PathContinue reading
C-Path Board Member Dr. Robert Califf Confirmed as New FDA Commissioner
Statement from Critical Path Institute Board Chair Wainwright Fishburn on the Senate Confirmation of Dr. Robert M. Califf, MD, MACC, as Commissioner of the U.S. Food and Drug Administration (FDA), Feb. 15, 2022.Continue reading
C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership
PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit organization, and the European Joint Programme on Rare Diseases (EJP RD), an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme, have announced a collaboration to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.Continue reading
C-Path Appoints Health Outcomes Expert as Executive Director of the Rare Disease COA Consortium
Dr. Lindsey Murray will lead C-Path’s New Rare Disease COA ConsortiumContinue reading
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium
The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseasesContinue reading
C-Path’s ePRO Consortium Announces Rebranding, Changes Name to eCOA Consortium
TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Reported Outcome (ePRO) Consortium is now the Electronic Clinical Outcome Assessment (eCOA) Consortium. This rebranding more accurately reflects the expanded portfolio range of work performed by the consortium, the actual capabilities of member firms and the scope and significance of the consortium’s role. The new name was chosen to more authentically characterize the mission and aims of the consortium, which have evolved significantly since its inception in 2011.Continue reading
C-Path and NICHD to Share Real-world Data to Advance Neonatal Drug Development
TUCSON, Ariz., Dec. 1, 2021 — Critical Path Institute’s (C-Path) International Neonatal Consortium (INC) today announced a seminal data-sharing collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health, as a part of a U.S. Food and Drug Administration (FDA) sponsored project to generate actionable real-world evidence (RWE) for neonatal drug development from real-world neonatal data (RWD).Continue reading
C-Path Joins New Coalition to Improve Patient Care and Address Unmet Medical Needs through Community-Level Clinical Trials
Tools being developed by C-Path’s CURE Drug Repurposing Collaboratory will help incorporate adaptive platform trial protocols in clinical practice.Continue reading
C-Path and Cure Mito Announce Data Sharing Agreement to Support Treatment Development For Leigh Syndrome and Mitochondrial Disease
TUCSON, Ariz., November 9, 2021 — Critical Path Institute (C-Path) and Cure Mito Foundation (Cure Mito) today announced a joint collaboration to significantly promote data sharing and accelerate Leigh syndrome and other rare mitochondrial disease data incorporation into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading